TY - JOUR
T1 - Complications of androgen deprivation therapy
T2 - Prevention and treatment
AU - Holzbeierlein, Jeffrey M.
AU - Castle, Erik
AU - Thrasher, J. Brantley
PY - 2004/3
Y1 - 2004/3
N2 - Androgen deprivation, as a form of treatment for prostate cancer, has been used for decades. Within the last decade, however, its use has increased significantly. Therefore, it is incumbent upon the physician to be familiar with the side effects associated with this treatment. Some of these side effects (eg, osteoporosis, changes in lipid profiles, and anemia) may be associated with significant morbidity, whereas others (eg, impotence, decreased libido, fatigue, and hot flashes) primarily affect the patient's quality of life. Prevention strategies and treatments exist for many of these side effects. In addition, alternative forms of antiandrogen therapy such as intermittent hormone ablation and antiandrogen monotherapy may be effective, with the added benefit of minimizing side effects. This review focuses on the wide range of side effects associated with androgen ablation as well aspreventive and treatment strategies.
AB - Androgen deprivation, as a form of treatment for prostate cancer, has been used for decades. Within the last decade, however, its use has increased significantly. Therefore, it is incumbent upon the physician to be familiar with the side effects associated with this treatment. Some of these side effects (eg, osteoporosis, changes in lipid profiles, and anemia) may be associated with significant morbidity, whereas others (eg, impotence, decreased libido, fatigue, and hot flashes) primarily affect the patient's quality of life. Prevention strategies and treatments exist for many of these side effects. In addition, alternative forms of antiandrogen therapy such as intermittent hormone ablation and antiandrogen monotherapy may be effective, with the added benefit of minimizing side effects. This review focuses on the wide range of side effects associated with androgen ablation as well aspreventive and treatment strategies.
UR - http://www.scopus.com/inward/record.url?scp=3042819408&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3042819408&partnerID=8YFLogxK
M3 - Review article
C2 - 15065701
AN - SCOPUS:3042819408
SN - 0890-9091
VL - 18
SP - 303
EP - 309
JO - Oncology
JF - Oncology
IS - 3
ER -